Global Status Epilepticus Treatment Market, By Type, (Conclusive Epilepticus, Non-conclusive Epilepticus), Condition (Epilepsy Drug Resistant, Intractable Epilepsy, Others), Drug (Ganaxolone, Diazepam, Fosphenytoin, Valproate, Phenobarbital, Phenytoin, and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Status Epilepticus Treatment Market Analysis and Size
The incidence of epileptic seizures is higher in low to middle-income countries, that drives the demand for epileptic seizure treatment is highly developed countries. As per the Epilepsy Foundation, only around 25 % of people who have Status Epilepticus will have Epilepsy and also in majority of the cases, it happens to children under the age of 15 years and to adult who are more than 40 years. There are several complications of status epilepticus that can range from no complications to death.
Data Bridge Market Research analyses a growth rate in the status epilepticus treatment market in the forecast period 2023-2030. The expected CAGR of status epilepticus treatment market is tend to be around 5 % in the mentioned forecast period. The market was valued at USD 1.21 billion in 2022, and it would grow up to USD 1.8 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Status Epilepticus Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type, (Conclusive Epilepticus, Non-conclusive Epilepticus), Condition (Epilepsy Drug Resistant, Intractable Epilepsy, Others), Drug (Ganaxolone, Diazepam, Fosphenytoin, Valproate, Phenobarbital, Phenytoin, and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
LivaNova PLC (U.K.), GSK Plc. (U.K.), Eisai Co., Ltd (Japan), Pfizer Inc. (U.S.), Medtronic (Ireland), UCB S.A.(Belgium), NeuroPace, Inc (U.S.), Jazz Pharmaceuticals, Inc (U.K.), Novartis AG (Switzerland), Johnson & Johnson Services, Inc. (India), Abbott (U.S.), Sage Therapeutics, Inc (U.S.), Marinus Pharmaceuticals, Inc. (U.S.), H. Lundbeck A/S (Denmark)
|
|
Market Opportunities
|
|
Market Definition
A status epileptic is a type of condition that is characterized by a seizure which involves abnormal electrical activity in the brain that can affect both mind and body. This problems can lead to have a seizure. The major symptoms that are related with status epileptics includes high fever, abnormal sodium or blood sugar levels, brain infections, and head injuries. Usually, in this condition, a seizure lasts for more than 5 minutes. The stroke, imbalance of blood sugar levels, drinking too much alcohol can simply leads to status epileptics disorders.
Status Epilepticus Treatment Market Dynamics
Drivers
- Increasing Incidence of Neurological Disorders
High occurrence of epilepsy and growing incidence of neurological disorder are anticipated to increase the demand for status epilepticus treatment, that is expected to drive the market growth during the forecast period. For instance, in June 2019, according to the World Health Organization (WHO), status epilepticus is a chronic, non-communicable central nervous system disease which affects more than 50 million individuals globally. Additionally, seizure recurrence is caused by abnormal brain activity. This boosts the market growth.
- Growing Number of Drug Developments
Developing potential drugs in pipeline is expected to drive the market during the forecast period. For instance, in October 2020, Marinus Pharmaceuticals initiated randomized clinical trial for drug Ganaxolone. This study assessed the effectiveness and safety of IV ganaxolone, for treating patients suffering from status epilepticus. Marinus Pharmaceuticals is about to begin patient enrollment in the drug ganaxolone Phase III RAISE research study.
Opportunities
- Rising Drug Approvals from Authorized Organizations
Growing approvals for status epilepticus treatment is estimated to boost the market growth during the forecast period. For instance, in April 2018, the U.S. FDA granted ZENEO (Midazolam) orphan drug designation to Crossject's treatment for status epilepticus. ZENEO is a pre-filled, single use device which can deliver a medical formulation through the skin in only about 50 milliseconds. The injection parameters of the device may be tailored to the dose, injection route of the medication formulation, and viscosity. Additionally, as per Crossject, ZENEO Midazolam allows for the fast treatment of epileptic seizures, with an average effect time of 1.2 minutes.
- Increased Government Initiatives and Funding
There have been increasing funding between different organizations that can lead to the growth of the market. For instance, in March 2021, American Epilepsy Society granted fund for prolonged epilepsy up to US$ 50,000 and are estimated to support the establishment of national or worldwide multicenter research initiatives. Each award will offer funding for organisational planning sessions, infrastructure development, or pilot studies, which allows the research programme to compete for future investment.
Restraints/Challenges
- High Cost of Treatment
The amplified expenditure that is required for the diverse treatment processes inhibit the market growth. Several market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process, and in return, the cost is increased.
This status epilepticus treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the status epilepticus treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Status Epilepticus Treatment Market Scope
The status epilepticus treatment market is segmented on the basis of types, condition, drug, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Conclusive Epilepticus
- Non-conclusive Epilepticus
Condition
- Epilepsy Drug Resistant
- Intractable Epilepsy
- Others
Drug
- Ganaxolone
- Diazepam
- Fosphenytoin
- Valproate
- Phenobarbital
- Phenytoin
- Others
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Status Epilepticus Treatment Market Regional Analysis/Insights
The status epilepticus treatment market is analyzed and market size insights and trends are provided by types, condition, drug, distribution channel and end-user as referenced above.
The major countries covered in the status epilepticus treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market because of the presence of several key manufacturers of the product is high and, increasing R&D activities.
Asia-Pacific is considered to grow over the upcoming years because of increased new research and developments on status epilepticus treatment market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Status Epilepticus Treatment Market Share Analysis
The status epilepticus treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to status epilepticus treatment market
Key players operating in the status epilepticus treatment market include:
- LivaNova PLC (U.K.)
- GSK Plc. (U.K.)
- Eisai Co., Ltd (Japan)
- Pfizer Inc. (U.S.)
- Medtronic (Ireland)
- UCB S.A.(Belgium)
- NeuroPace, Inc (U.S.)
- Jazz Pharmaceuticals, Inc (U.K.)
- Novartis AG (Switzerland)
- Johnson & Johnson Services, Inc. (India)
- Abbott (U.S.)
- Sage Therapeutics, Inc (U.S.)
- Marinus Pharmaceuticals, Inc.(U.S.)
- H. Lundbeck A/S (Denmark)
SKU-